Company intelligence / Profile preview

Inspirion Delivery Sciences

Morristown, New Jersey, United Statesdaiichisankyo.com ↗

Ownership: Private
Employees: ~24
Development stage: Commercial

Overview

Inspirion developed FDA-approved abuse-deterrent opioid formulations, including MorphaBond ER (morphine sulfate extended-release) and RoxyBond (oxycodone immediate-release), both commercialized in the U.S. via partnership with Daiichi Sankyo. The SentryBond platform imparts physical and chemical barriers to deter common methods of prescription opioid abuse.

Therapeutic areas: Neurology
Modalities: Small moleculeAbuse-deterrent formulation technology
Industry: Biotech

Drug pipeline

1 asset

morphine sulfate

Commercial

Indications: Chronic pain

Partnerships

Daiichi Sankyo Inc. (U.S. commercialization partner for MorphaBond ER and RoxyBond)

Beyond the preview

Go deeper on Inspirion Delivery Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inspirion Delivery Sciences.

Explore the full profile